Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
Eun Kyoung Jeon, Sook Hee Hong, Tae Hee Kim, Seung Eun Jung, Ji Chan Park, Hye-Sung Won, Yoon-Ho Ko, Sang Young Rho, Young Seon Hong
Cancer Res Treat. 2011;43(3):148-153. Published online 2011 Sep 30 DOI: https://doi.org/10.4143/crt.2011.43.3.148
Citations to this article as recorded by 
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Ana Fernández Montes, Carlos López López, Guillem Argilés Martínez, David Páez López, Ana María López Muñoz, Beatriz García Paredes, David Gutiérrez Abad, Carmen Castañón López, Paula Jiménez Fonseca, Javier Gallego Plazas, María Carmen López Doldán, Eva
The Oncologist.2019; 24(8): e687. CrossRef
Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition
Chinnadurai Mani, Sachin Pai, Cinta Maria Papke, Komaraiah Palle, William H. Gmeiner
Neoplasia.2018; 20(12): 1236. CrossRef
Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer
Zheng Chen, Zhenyu Zhou, Zhigang Hu, Qiaodong Xu, Jie Wang
Oncology Letters.2017;[Epub] CrossRef
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, Peter C. Thuss-Patience, Joern Ruessel, Susanna Hegewisch-Becker, Hansjochen Wilke, Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, Florian Weißinger, Hans-Joachim Schmoll, Frank Kullmann, Ludwig Fischer v
BMC Cancer.2016;[Epub] CrossRef
5-Fluorouracil derivatives: a patent review (2012 – 2014)
Esmeralda Carrillo, Saúl Abenhamar Navarro, Alberto Ramírez, María Ángel García, Carmen Griñán-Lisón, Macarena Perán, Juan Antonio Marchal
Expert Opinion on Therapeutic Patents.2015; 25(10): 1131. CrossRef
Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer
Sung Chul Park, Hoon Jai Chun
The Korean Journal of Gastroenterology.2015; 66(1): 1. CrossRef
Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer
Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim
The Korean Journal of Gastroenterology.2015; 66(1): 10. CrossRef
FOLFIRI as Second-line Chemotherapy after Failure of FOLFOX4 in Advanced Colorectal Cancer: A Korean Single-center Experience
Jae Hyun Kim, Seun Ja Park, Moo In Park, Won Moon, Sung Eun Kim, Ki Hwan Ku, Sung Eun Song, Je Hun Kim
The Korean Journal of Gastroenterology.2014; 63(1): 18. CrossRef
5-Fluorouracil derivatives: a patent review
Pablo Álvarez, Juan Antonio Marchal, Houria Boulaiz, Esmeralda Carrillo, Celia Vélez, Fernando Rodríguez-Serrano, Consolación Melguizo, Jose Prados, Roberto Madeddu, Antonia Aranega
Expert Opinion on Therapeutic Patents.2012; 22(2): 107. CrossRef
Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
Cancer Research and Treatment.2012; 44(4): 235. CrossRef
Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer
JUNG HAN KIM, HYEONG SU KIM, A RUM HAN, IN HO MOH, DOO CHEOL CHUNG, DAE RO CHOI, HYUN JOO JANG, JIN BAE KIM, DAE HYUN YANG, SOON IL LEE, DAE YOUNG ZANG
Oncology Letters.2012; 4(4): 751. CrossRef